Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPREDDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, NIHR Biomedical Research Centre, University of Manchester and Manchester Academic Health Science Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.
Department of Pulmonary Medicine, University Hospital and University of Bern, Bern, Switzerland.
NIHR Southampton Biomedical Research Centre, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Department of Pulmonology, Semmelweis University, Budapest, Hungary; National Koranyi Institute for Pulmonology, Budapest, Hungary.
Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Hannover, Germany.
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine.
Paediatric Respiratory Medicine, Children’s University Hospital of Bern, University of Bern, Bern, Switzerland; Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
Department of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Respiratory Research Unit, University of Nottingham, Nottingham, United Kingdom.
Catholic University of the Sacred Heart, Rome, Italy; National Heart and Lung Institute, Imperial College, London, United Kingdom.
Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
NIHR Southampton Biomedical Research Centre, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; The David Hide Asthma and Allergy Research Centre, St Mary’s Hospital, Newport, United Kingdom.
National Heart and Lung Institute, Imperial College, London, United Kingdom.
Università Campus Bio-Medico IT, Rome, Italy.
Department of Respiratory Medicine, GIGA I 3, CHU Sart-TilmanB35, University of Liege, Liege, Belgium.
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.
BioSci Consulting, Maasmechelen, Belgium.
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden; Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
National Heart and Lung Institute, Imperial College, London, United Kingdom; Respiratory Department, Royal Brompton & Harefield Hospital, London, United Kingdom.
National Heart and Lung Institute, Imperial College, London, United Kingdom.
NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands; Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, Netherlands.
Show others and affiliations
2024 (English)In: Health and Quality of Life Outcomes, E-ISSN 1477-7525, Vol. 22, no 1, article id 109
Article in journal (Refereed) Published
Abstract [en]
Rationale: Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.
Objectives: To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.
Methods: Data of 421 patients with severe asthma (62% female; mean age 51.9 ± 13.4 years; mean FEV1 67.5 ± 21.3%pred) from the U-BIOPRED cohort were analyzed. The included PROMs were: Asthma Control Questionnaire (ACQ5); Asthma Quality of Life Questionnaire (AQLQ); Hospital Anxiety and Depression scale (HADS); Epworth Sleepiness Scale (ESS); Medication Adherence Report Scale (MARS); Sino-Nasal Outcomes Test (SNOT20). Participants were assessed at baseline and after 12–18 months of usual care.
Results: PROMs showed very weak to weak correlations with clinical characteristics such as age, body mass index, FEV1, FeNO and eosinophilic cell count. Patients presenting no exacerbations during follow-up showed a statistically significant improvement in all PROMs (except for MARS), whereas individuals experiencing > 2 exacerbations showed a deterioration. Baseline ACQ5 was a predictor of exacerbations with an AUC of 0.590 (95%CI 0.514–0.666).
Conclusions: The association of PROMs with clinical measures was poor in severe asthmatics. Moreover, PROMs were prone to changes in usual care, with exacerbations playing a key role. PROMs need to be systematically evaluated in severe asthma to improve clinical care based on specific patient’s needs.
Place, publisher, year, edition, pages
BioMed Central (BMC), 2024. Vol. 22, no 1, article id 109
Keywords [en]
Health status, Obstructive pulmonary diseases, Patient outcome assessment
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:umu:diva-233746DOI: 10.1186/s12955-024-02321-3ISI: 001381573200001PubMedID: 39707320Scopus ID: 2-s2.0-85212983211OAI: oai:DiVA.org:umu-233746DiVA, id: diva2:1925333
Funder
EU, FP7, Seventh Framework Programme, FP7/2007–20132025-01-082025-01-082025-01-08Bibliographically approved